Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531566 | 0.90 | ALDH1A1 (0.41) | HRH2HRH1CYP11B2CYP2A6NSD2 | |
| SCHEMBL7634772 | 0.84 | ALDH1A1 (0.48) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL6062294 | 0.83 | EGLN2 (0.41) | EGLN2CYP11B2CYP11B1 | |
| SCHEMBL27806613 | 0.83 | KIF11 (0.47) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL23625527 | 0.81 | ALDH1A1 (0.56) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL2786090 | 0.78 | MMP3 (0.57) | HRH2HRH1EGLN2CYP11B2CYP11B1 | |
| SCHEMBL12496569 | 0.78 | PTGS1 (0.49) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL17629909 | 0.78 | MAOA (0.43) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL14525302 | 0.78 | HRH2 (0.41) | HRH2HRH1PDE3BPDE3AEGLN2 | |
| SCHEMBL2572264 | 0.78 | ESR2 (0.53) | EGLN2CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | DDT, DDC, DARS1 | HRH2 815/4885HRH1 838/4885PDE3B 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.